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Metabolic Effects of Darunavir/Ritonavir Versus
Atazanavir/Ritonavir in Treatment-Naive,
HIV Type 1-Infected Subjects over 48 Weeks
Judith A. Aberg,1 Pablo Tebas,2 Edgar Turner Overton,3 Samir K. Gupta,4 Paul E. Sax,5
Alan Landay,6 Ron Falcon,7 Robert Ryan,8 and Guy De La Rosa9
Abstract
We assessed metabolic changes for darunavir/ritonavir (DRV/r) once daily (qd) versus atazanavir/ritonavir
(ATV/r) qd with fixed-dose tenofovir/emtricitabine. This was a phase 4, multicenter, open-label, randomized
exploratory study. Treatment-naive, HIV-1-infected adults received DRV/r 800/100mg qd or ATV/r 300/
100mg qd, both with emtricitabine/tenofovir 200/300mg qd. Primary end point: change in triglyceride levels
from baseline to week 12. Secondary end points: week 12 and week 48 changes in lipid parameters, insulin
sensitivity, inflammatory/coagulation/bacterial translocation biomarkers, viral load, CD4+ cell count, and week
48 changes in adipose tissue distribution and subjects’ perceptions of body changes. In the DRV/r arm, 32/34
and 29/34 subjects completed weeks 12 and 48, respectively; in the ATV/r arm, 30/31 and 25/31 subjects
completed weeks 12 and 48, respectively. Small changes in lipid parameters from baseline to weeks 12 and 48
were observed in both arms. Differences were noted between arms in mean changes in total cholesterol (DRV/r,
20.3mg/dl; ATV/r, 4.6mg/dl) and apolipoprotein A1 (DRV/r, 10.7mg/dl; ATV/r, –0.7mg/dl) at week 12. At
week 48, no clinically relevant differences between arms were noted for changes in any lipid parameter, fasting
glucose, or insulin sensitivity. Biomarkers generally decreased and efficacy parameters improved in both arms
over 48 weeks. Changes in adipose tissue were small and comparable between arms. Subjects’ perceptions of
body changes generally improved in both study arms. This first pilot comparison in HIV-1-infected subjects
suggests that DRV/r has a metabolic profile similar to ATV/r over 48 weeks of treatment. Further randomized
studies are warranted.
Introduction
HIV-infected individuals have a heightened risk of se-rious non-AIDS conditions, such as cardiovascular dis-
ease (CVD), compared with uninfected individuals, due to
HIV-induced activation of inflammation and coagulation
pathways.1,2 Antiretroviral (ARV) agents, including protease
inhibitors (PIs), also contribute to this increased risk as a result
of their metabolic complications.3 Specifically, some ritonavir-
boosted PIs have been associated with a worsening of lipid
parameters and increases in inflammatory markers.4–7 Ad-
ditionally, some PIs have been associated with insulin resis-
tance in HIV-negative healthy volunteers.8–11 However, this
association with insulin resistance seems to be ARV-specific,
as opposed to class-specific, as studies evaluating other PIs
have failed to demonstrate such an association.12,13 The met-
abolic complications associated with PI-based therapy can
develop within the first week after treatment initiation.6,14–18
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Commonly prescribed PIs exert differential effects on lipid,
glucose, and insulin parameters, and comprehensive assess-
ment of these metabolic effects will clarify the optimal treat-
ment choices.
Thymidine analogs and, to a lesser degree, PIs and non-
nucleoside reverse transcriptase inhibitors have also been
associated with lipoatrophy and lipodystrophy.5,19–22 In the
HIV-1-infected population, lipodystrophy is an umbrella term
that encompasses all changes in fat distribution, including
lipohypertrophy, which can include accumulation of fat in the
neck, chest, back, breasts, and/or abdomen, and lipoatrophy,
which may include fat loss from the limbs, buttocks, and/or
face.23–25 HIV-1-associated changes in body shape have the
potential to impact a subject’s quality of life and well-being,
and several studies have linked quality of life to survival of
HIV-1-infected subjects.26–28 Interestingly, subjects’ percep-
tions of the changes to their body during ARV therapy are not
always in accordance with the objective changes measured in
a clinical setting.29 Despite this, few studies have specifically
investigated subjects’ perceptions of changes in their bodies
due to ARV therapy.30,31
Darunavir (DRV; PREZISTA, Janssen Therapeutics, Divi-
sion of Janssen Products, LP, Titusville, NJ), a PI, combined
with low-dose ritonavir (DRV/r), has a favorable lipid profile
in healthy and treatment-naive subjects.32,33 Another PI, ata-
zanavir (ATV; REYATAZ, Bristol-Myers Squibb, Princeton,
NJ), boosted with low-dose ritonavir (ATV/r), has also
demonstrated a favorable metabolic profile in treatment-na-
ive subjects.34 The metabolic effects of DRV/r have been
shown to be comparablewith those of ATV/r inHIV-negative
subjects.33 Furthermore, the metabolic effects of these ARVs
have not been directly compared in HIV-1-infected, treatment-
naive subjects.
Presented here are the week 12 primary end point analysis
and the week 48 results of METABOLIK (Metabolic Evalua-
tion in Treatment-naı¨ves Assessing the impact of two BOosted
protease inhibitors on LIpids and other marKers), an explor-
atory study evaluating metabolic outcomes of DRV/r-based
therapy compared with those of ATV/r-based therapy in
treatment-naive, HIV-1-infected adult subjects. Additionally,
we report changes in adipose tissue distribution and subjects’
perceptions of body changes over the course of the trial.
Materials and Methods
Study design and treatment
METABOLIK was a 48-week, phase 4, multicenter, open-
label, randomized study that assessed changes in fasting lip-
ids, glucose, insulin, insulin sensitivity, biomarkers, and the
safety and efficacy of DRV/r-based versus ATV/r-based
therapy in HIV-1-infected, treatment-naive adults. Adult
subjects were randomized in a 1:1 ratio, stratified by sex, to
receive DRV/r 800/100mg once daily (qd) or ATV/r 300/
100mg qd, both with a fixed-dose combination of em-
tricitabine/tenofovir disoproxil fumarate (FTC/TDF) 200/
300mg qd. Both DRV and ATV, with ritonavir, were admin-
istered within 30min of a meal to maximize drug exposure.
Subject population
Eligible subjects were at least 18 years old and naive to ARV
therapy (£ 10 days’ previous ARV therapy at any point) with
HIV-1 RNA 1000 copies/ml or higher; there were no CD4 +
count restrictions. Subjects were required to have demon-
strated sensitivity to DRV, ATV, TDF, and FTC by resistance
testing (DRV, ATV, and TDF susceptibility determined by
Antivirogram, Virco Lab, Inc., Raritan, NJ; FTC susceptibility
determined by virco TYPE HIV-1, Virco Lab, Inc., Raritan,
NJ). Exclusion criteria included body mass index greater
than 30 kg/m2; fasting glucose greater than 110mg/dl; low-
density lipoprotein (LDL) greater than 130mg/dl; triglycer-
ides greater than 200mg/dl; alanine aminotransferase greater
than 2.5 times the upper limit of normal; creatinine clearance
50ml/min/m2 or lower; evidence of significantly decreased
hepatic function or decompensation; presence of any Centers
for Disease Control and Prevention active AIDS-defining
illness (Category C conditions), except stable cutaneous
Kaposi’s sarcoma or wasting syndrome; acute or chronic
hepatitis A, B, or C; grade 3 or 4 laboratory abnormalities;
history of significant cardiac, vascular, pulmonary, gastroin-
testinal, endocrine, neurologic, hematologic, rheumatologic,
psychiatric, or metabolic disturbances; use of any non-
ARV investigational agents within 90 days of screening; re-
ceipt of anabolic steroids, atypical antipsychotics, or growth
hormones; use of disallowed concomitant therapy; and
pregnancy or breastfeeding. Use of lipid-lowering medica-
tions, either prescription (e.g., statins or fibrates) or over-
the-counter (e.g., fish oil), was prohibited from 28 days before
baseline through week 12 of the trial. The use of lipid-lowering
medications was allowed after week 12. All subjects provided
written informed consent.
Study evaluations
The primary end point was the change in triglyceride levels
from baseline to week 12. Secondary end points included
week 12 and week 48 changes in other lipid parameters that
included total cholesterol (TC), high-density lipoprotein
(HDL), LDL, and apolipoproteins (apo) A1 and B. Lipid pa-
rameters were tested for normality. Additional secondary end
points assessed at week 12 and week 48 included changes in
glucose and insulin levels, insulin sensitivity (as measured by
the homeostasis model assessment of insulin resistance
[HOMA-IR] method),35 inflammatory biomarkers (interleu-
kin [IL]-1 beta, IL-6, tumor necrosis factor receptor II [TNF
RII], high sensitivity C-reactive protein [hs-CRP]), coagula-
tion biomarkers (fibrinogen, d-dimer), and the microbial
translocation biomarker lipopolysaccharide (LPS). In addi-
tion, polychromatic flow cytometry was used to assess
changes in the percentage of CD3+/CD4+ and CD3+/CD8+ T
cells, along with their markers of immune activation (CD38+/
HLADR+); senescence (CD28-/CD57+); proliferation (Ki67+);
and naive/memory subsets (naive, CCR7+/CD45RA+; central
memory, CCR7+/CD45RA-; effector memory, CCR7-/
CD45RA-; terminal effector, CCR7-/CD45RA+).
For measuring insulin sensitivity, HOMA-IR was calcu-
lated using the following formula: {[fasting insulin (lU/
ml)] · [fasting glucose (mmol/liter)]}/22.5.36 The lower limits
of quantification (laboratory variability; normal reference
range) for the biomarker assays are as follows: IL-1 beta,
0.125 pg/ml (6.7%; < 0.201 pg/ml); IL-6, 0.2 pg/ml (4.3%;
< 11.83 pg/ml); TNF RII, 1 pg/ml (2.6%–4.8%; 1003–3170 pg/
ml); hs-CRP, 0.15mg/liter ( < 2%; < 5.00mg/liter); fibrinogen,
42mg/dl (< 4%; 211–372mg/dl); and d-dimer, 109 ng/ml
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( < 4%; < 201 ng/ml; ICON Central Laboratories Inc., Farm-
ingdale, NY). For the determination of LPS concentration, the
QCL-1000 assay (Lonza Biologics Inc., Walkersville, MD),
with a sensitivity range of 0.1–1.0 endotoxin units/ml (1 en-
dotoxin unit = 100 pg), and low intraassay variability, was
used. Change in log10 HIV-1 RNA from baseline, proportion
of subjects with virologic response (HIV-1 RNA < 50 copies/
ml), change in CD4+ cell count through week 48, and safety
were also assessed.
For analysis of fat redistribution, computed tomography
(CT) scans were performed at the L4–L5 level and mid-thigh
at baseline and week 48, and centrally analyzed for total
(TAT), subcutaneous (SAT), visceral (VAT), and peripheral
(PAT) adipose tissue by BioClinica Imaging Technologies, Inc.
(Newtown, PA). The 27-item, self-reported Assessment of
Body Change and Distress (ABCD) questionnaire37 was ad-
ministered at baseline and at weeks 12 and 48 and was com-
posed of three parts. The categorical portion of the
questionnaire asked subjects to assign one of five answers,
ranging from ’’all of the time’’ to ’’none of the time,‘‘ to
questions encompassing a wide range of disease-related is-
sues. The yes/no portion of the questionnaire asked subjects
to indicate whether they had noticed changes in aspects of
their physical appearance. Finally, the questionnaire asked
subjects to rate their overall satisfaction with their body. The
questionnaire had a recall period of 4 weeks and measured
subjects’ perceived body changes, physical and emotional
distress, social concerns, and health behavioral changes. Re-
sponses to the ABCD questionnaire were not considered or
reported as adverse events (AEs).
Fasting (at least 8 h) blood samples for laboratory assess-
ments, lipids, and efficacy parameters were taken at weeks 0,
4, 8, 12, 24, 36, and 48, and for biomarker tests at weeks 0, 4, 12,
24, and 48. Lipid parameters, glucose, and insulin assessments
were analyzed by ICON Central Laboratories (Farmingdale,
NY). Biomarkers were analyzed by Rush University Medical
Center (Chicago, IL) and ICON Central Laboratories. The
incidence and type of all AEs and serious AEs (SAEs) were
recorded from the signing of the informed consent form
through the completion of the last study-related procedure.
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000.
Statistical analysis
The primary end point for this study was change in tri-
glyceride levels from baseline to week 12. Assuming a
standard deviation (SD) of 75mg/dl for the primary end
point and a two-sided 95% confidence interval (CI) with a
precision of 42mg/dl on each side of the estimated differ-
ence, it would be required that at least 50 subjects complete
the study (25 subjects per treatment arm). To allow for
dropouts, an overall sample size of 60 subjects was planned.
Descriptive statistics for the preplanned analyses of the pri-
mary and secondary end points at week 12 and week 48 are
reported. The lipid-evaluable population used for the week
12 andweek 48 lipid end points includes subjects completing
week 12 who had a baseline value and at least one postdose
fasting lipid value and no relevant protocol deviations or
violations; lipid analyses were completed using observed val-
ues. All other end points use observed values for the intent-to-
treat (ITT) population. The lipid and biomarker end points were
estimatedusingmean valueswith 95%CIs. Response rateswere
derived using the confirmed virologic response (CVR; HIV-1
RNA<50 copies/ml, confirmed by two consecutive assess-
ments at least 14 days apart) algorithm for the ITT population.
Results
Subject population and baseline characteristics
In total, 34 subjects (29 men) received DRV/r-based regi-
mens and 31 (27 men) received ATV/r-based regimens. In the
DRV/r arm, 32 subjects completed week 12 and 29 subjects
completed week 48; in the ATV/r arm, 30 and 25 subjects
completed week 12 and week 48, respectively. The lipid-
evaluable populations included 28 and 27 subjects in the
DRV/r andATV/r arms, respectively. Of five (14.7%) subjects
in the DRV/r arm who discontinued prior to week 48, two
withdrew consent, one was noncompliant, one was lost to
follow-up, and one relocated. Of six (19.4%) subjects in the
ATV/r arm who discontinued early, two discontinued due to
AEs (one with grade 3 leukocytoclastic vasculitis and one
with grade 1 increased blood creatinine), one discontinued
due to pregnancy, one discontinued because of investiga-
tional product dispensing error, one was lost to follow-up,
and one withdrew consent. At baseline, DRV/r subjects had
higher mean log10 baseline viral loads, lower median CD4
+
counts, and lower TC and LDL levels compared with ATV/r
subjects (Tables 1 and 2).
Over the course of the study, the median duration of ex-
posure to DRV or ATV was similar in the DRV/r (337 days)
Table 1. Baseline Demographics and Disease
Characteristics
DRV/r ATV/r
Parameter n = 34 n = 31
Male, n (%) 29 (85.3) 27 (87.1)
Age, median
(range), years
36.5 (19.0–58.0) 35.0 (20.0–65.0)
Race, n (%)
Asian 0 2 (6.5)
Black 13 (38.2) 17 (54.8)
White 21 (61.8) 12 (38.7)
Ethnicity, n (%)
Hispanic/Latino 7 (20.6) 7 (22.6)
BMI, mean (SD) 23.8 (3.1) 24.5 (3.6)
Worst clinical stage of
HIV infection, n (%)
A 30 (88.2) 26 (83.9)
B 4 (11.8) 4 (12.9)
C 0 1 (3.2)
CD4 + count, median
(range), cells/mm3
267 (10–532) 316 (39–813)
Viral load, mean (SD),
log10 copies/ml
5.0 (0.8) 4.6 (0.7)
Viral load, median
(range), copies/ml
137,000
(642–2,450,000)
46,100
(397–637,000)
DRV/r, darunavir/ritonavir; ATV/r, atazanavir/ritonavir; BMI,
body mass index; SD, standard deviation.
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and ATV/r (336 days) arms. No subjects received lipid-
lowering medications after week 12.
Lipid evaluations
Primary end point: week 12 change in triglyceride
levels. From baseline to week 12, triglyceride levels in-
creased by a mean of 22.0mg/dl (SD: 62.7) in the DRV/r arm
and 8.1mg/dl (SD: 81.2; Table 2) in the ATV/r arm. The
difference in week 12 mean change (95% CI) between the
DRV/r and ATV/r arms was 13.8 (–25.8, 53.4). A sensitivity
analysis was conducted on the changes in triglyceride levels
using normalized (natural log) triglyceride data, yielding
similar results.
Secondary end points. Small changes in other lipid pa-
rameters were noted with DRV/r therapy from baseline to
week 12 (Table 2). Between arms, differences in lipid changes
were seen only in TC and apoA1, with the DRV/r arm ex-
periencing greater changes in both parameters than the ATV/
r arm. The difference in week 12 mean change between arms
(95% CI) was 15.7mg/dl (0.0, 31.3) for TC (20.3mg/dl in the
DRV/r group and 4.6mg/dl in the ATV/r group) and
11.4mg/dl (0.7, 22.1) for apoA1 (10.7mg/dl in the DRV/r
group and –0.7mg/dl in the ATV/r group) (Table 2). The
actual mean TC values at week 12 were 161.5mg/dl and
169.7mg/dl for DRV/r and ATV/r, respectively, while the
actual mean apoA1 values at week 12 were 125.6mg/dl and
126.8mg/dl for DRV/r and ATV/r, respectively. Consistent
with the week 12 results, no clinically meaningful difference
was seen between arms for mean changes in triglyceride
levels at week 48. In contrast to the week 12 results, changes
in TC and apoA1 were similar between arms by week 48
(Table 2). Additionally, no clinically relevant differences be-
tween arms were noted for changes in the other fasting lipid
parameters, including the apoB/apoA1 ratio, at week 48
(Table 2). Changes from baseline for the lipid parameters were
generally normally distributed.
Other laboratory evaluations and biomarkers
No clinically relevant changes were seen from baseline to
week 12, or baseline to week 48, in glucose, insulin, and in-
sulin sensitivity with DRV/r or ATV/r therapy (Table 2).
Biomarkers of inflammation, coagulation and microbial
translocation generally decreased from baseline to week 12 in
both treatment arms (Table 2). From baseline to week 48, fi-
brinogen, d-dimer, TNF RII, and LPS decreased in both
treatment arms, while hs-CRP and IL-6 demonstrated small
increases in both arms (Table 2). Small increases in IL-1 beta
were seen in the DRV/r arm, whereas small decreases were
observed in the ATV/r arm, from baseline to week 48. At both
time points, differences were noted between arms for changes
in TNF RII, with the DRV/r arm experiencing greater de-
creases than the ATV/r arm.
Adipose tissue distribution
At baseline, subjects in the ATV/r arm had higher mean
values for all CT scan parameters compared with subjects in
the DRV/r arm (Table 3). Changes in TAT, VAT, SAT, and
the SAT/VAT ratio from baseline to week 48 were small and
comparable between the DRV/r and ATV/r arms (Table 3).
Although the mean change in PAT over 48 weeks was larger
in the DRV/r arm than in the ATV/r arm (Table 3), none of
the changes in adipose tissue distribution over 48 weeks was
considered clinically relevant.
Assessment of Body Change andDistress questionnaire
Subjects’ perceptions of body changes generally improved
from baseline to week 48 in both study arms. Overall, higher
proportions of subjects in both arms were ‘‘satisfied’’ or ‘‘very
satisfied’’ with their bodies after 48 weeks compared with
baseline (Fig. 1A). Within each study arm, responses to the
categorical portion of the ABCD questionnaire were similar at
baseline and at week 48, with few subjects switching cate-
gories. Furthermore, these categorical responses were also
similar between the DRV/r and ATV/r arms at both time
points.
In the yes/no portion of the ABCD questionnaire (Fig.
1B), more subjects in both the DRV/r and ATV/r arms
reported increases in waist size at week 48 compared with
baseline (DRV/r, 46.4% vs. 9.1%; ATV/r, 32.0% vs. 12.9%).
Fewer subjects in both the DRV/r and ATV/r arms
Table 3. Change in Adipose Tissue Distribution from Baseline to Week 48
DRV/r ATV/r
n = 34 n = 31
BL
Change from
BL to week 48 BL
Change from
BL to week 48
Difference in
mean change between
arms (95% CI)
Abdomen n529 n520 n530 n524
TAT, mean (SD), cm2 258.7 (89.38) 24.2 (98.40) 285.1 (120.80) 29.4 (38.32) - 5.20 ( - 49.19, 38.79)
VAT, mean (SD), cm2 97.6 (47.10) - 0.6 (49.20) 102.5 (44.60) 3.8 (24.48) - 4.38 ( - 27.43, 18.67)
SAT, mean (SD), cm2 161.1 (74.06) 24.8 (56.50) 182.7 (108.37) 25.6 (28.20) - 0.82 ( - 27.31, 25.67)
VAT/SAT ratio,
mean (SD)
0.50 (0.281) 0.00 (0.135) 0.53 (0.289) - 0.04 (0.104) 0.04 ( - 0.03, 0.11)
Mid-thigh n529 n521 n527 n521
PAT, mean (SD), cm2 55.4 (25.74) 7.0 (17.32) 61.0 (38.06) - 1.9 (9.53) 8.88 (0.16, 17.60)
DRV/r, darunavir/low-dose ritonavir; ATV/r, atazanavir/low-dose ritonavir; CI, confidence interval; BL, baseline; TAT, total
adipose tissue; SD, standard deviation; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; PAT, peripheral adipose
tissue.
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reported that they had lost fat in their buttocks or in
their arms and legs or that their cheeks had sunken in at
week 48, compared with baseline. Slightly more subjects in
the DRV/r arm and slightly fewer subjects in the ATV/r
arm reported gaining fat at the back of their neck at week 48
compared with baseline. Although responses to this portion
of the questionnaire were generally similar between arms,
more subjects in the DRV/r arm reported increases in waist
and chest size at week 48 compared with subjects in the
ATV/r arm (Fig. 1B).
FIG. 1. Results of the Assessment
of Body Change and Distress
questionnaire: (A) categorical and
(B) yes versus no. *Data were
missing from one ATV/r subject at
week 48; DRV/r, darunavir/low-
dose ritonavir; ATV/r, atazanavir/
low-dose ritonavir; BL, baseline; Wk,
week.
(Figure continued/)
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Efficacy evaluations
Viral load and CD4+ cell count improved over the course of
the study. Mean viral load decreased and mean CD4+ count
increased from baseline toweek 48 in both the DRV/r (change
in log10 viral load, –3.3 copies/ml; change in CD4
+ count,
+ 217.4 cells/mm3) and ATV/r arms (change in log10 viral
load, –2.9 copies/ml; change in CD4+ count, + 205.3 cells/
mm3). At week 48, 76.5% of DRV/r and 71.0% of ATV/r
subjects (CVR) achieved virologic response.
Cellular activation and senescence
The proportion of CD4+ and CD8+ cells displaying markers
of cellular activation (HLADR+/CD38+), proliferation (Ki67+),
and senescence (CD28-/CD57+) generally decreased from
baseline to week 48 (Table 4). There was also a general increase
in the percent of naive CD4+ andCD8+ T cells in both treatment
arms.
Safety evaluations
Over 48 weeks, rates of AEs were generally low and com-
parable between theDRV/r andATV/r arms (Table 5), except
grade 2–4 hyperbilirubinemia (considered at least possibly
related to study drug), which was observed in more ATV/r
subjects than DRV/r subjects. Increased total bilirubin re-
ported as a grade 2–4 laboratory abnormality was observed
far more frequently in the ATV/r arm compared with the
FIG. 1. Continued.
Table 4. Markers of Immune Activation and Senescence over 48 Weeks
(Intent-to-Treat Population, Observed Values)
DRV/r ATV/r
Parameter, mean % (SD) BL Week 48 BL Week 48
CD41
Naive (CCR7+/CD45RA+) 47.9 (21.14) 54.7 (19.55) 38.9 (21.10) 49.1 (20.91)
Central memory (CCR7+/CD45RA-) 11.9 (8.45) 14.2 (9.37) 19.1 (14.49) 15.0 (7.22)
Terminal effectors (CCR7-/CD45RA+) 10.9 (5.50) 9.4 (3.43) 12.1 (8.78) 11.4 (7.88)
Effector memory (CCR7-/CD45RA-) 29.3 (18.85) 21.7 (16.76) 30.0 (12.03) 24.5 (15.00)
CD38+/HLADR+ 13.6 (7.10) 8.5 (4.50) 13.0 (10.82) 10.9 (5.44)
Ki67+ 1.9 (1.52) 0.9 (0.86) 1.6 (1.55) 1.0 (0.97)
CD28-/CD57+ 7.7 (12.75) 1.7 (1.50) 9.1 (14.72) 3.5 (5.57)
CD81a
Naive (CCR7+/CD45RA+) 13.6 (10.09) 25.4 (15.63) 15.4 (9.89) 26.1 (12.33)
Central memory (CCR7+/CD45RA-) 12.37 (12.43) 8.7 (8.70) 16.2 (10.32) 8.5 (7.11)
Terminal effectors (CCR7-/CD45RA+) 26.4 (14.91) 27.2 (11.07) 26.0 (16.67) 33.9 (14.19)
Effector memory (CCR7-/CD45RA-) 47.7 (14.85) 38.7 (14.42) 42.4 (14.85) 31.4 (11.40)
CD38+/HLADR+ 43.8 (17.75) 19.4 (12.49) 40.5 (17.51) 22.2 (11.05)
Ki67+ 2.8 (1.75) 1.2 (0.75) 2.3 (2.06) 1.2 (0.78)
CD28-/CD57+ 32.1 (11.81) 19.6 (12.32) 31.8 (15.02) 22.8 (15.06)
Sample size varies by time point and parameter.
aCD8+ cell subpopulations were based on CD8+ percentages and were not directly measured.
SD, standard deviation; DRV/r, darunavir/ritonavir; ATV/r, atazanavir/ritonavir; BL, baseline; HLADR, human leukocyte antigen-DR.
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DRV/r arm (Table 5). No other major differences in grade 2–4
safety parameters were noted between arms. A total of 10
subjects (Table 5) experienced 16 SAEs. Three events, chronic
obstructive pulmonary disease with respiratory distress
(DRV/r arm), diabetes mellitus (DRV/r arm), and mitral
valve incompetence (ATV/r arm), were grade 4 in severity; all
three were considered not related to study medication. Of
the 16 SAEs, only one event, grade 3 pancreatitis in a subject in
the DRV/r arm, was considered possibly related to study
medication. No clinically relevant changes in creatinine
clearance were seen from baseline to week 48 in the DRV/r
[mean (SD) change: –0.00 (0.288) ml/min] or ATV/r [mean
(SD) change: –0.03 (0.244) ml/min] arm.
Discussion
These results illustrate that changes in triglyceride levels
over 12 weeks of treatment were similar in subjects treated
withDRV/r-based andATV/r-based regimens. Additionally,
small changes in lipids and insulin sensitivity, decreases in
biomarkers, small changes in body fat, improvements in ef-
ficacy parameters, and a low incidence of AEs were seen over
48 weeks in both treatment arms. In the DRV/r arm, the
increase in apoA1, the major component of HDL, indicates
favorable lipid changes that support the return-to-health
phenomenon observed in subjects with lower CD4+ cell
counts initiating ARV therapy.38 The small changes in lipids
seen in this trial with DRV/r are in agreement with results
from the ARTEMIS (AntiRetroviral Therapy with TMC114
ExaMined In naı¨ve Subjects) trial of 689 treatment-naive
subjects, which showed that once-daily DRV/r had a more
favorable metabolic profile compared with that of lopinavir
(LPV)/r.39
Subjects infected with HIV-1 have increased levels of hs-
CRP, TNF alpha (TNF-a), IL-6, d-dimer, and other biomarkers
compared with HIV-negative subjects.2,40–42 These elevations
in biomarkers persist even after virologic suppression, likely
due to HIV-induced activation of inflammation and coagu-
lation pathways.2 Levels of TNF-a, IL-6, hs-CRP, and other
proinflammatory cytokines are associated with HIV-1 viral
load and may predict disease progression, as well as correlate
with a higher risk of CVD and all-cause mortality.42–45 Our
findings corroborate another recent analysis, which reported
that only d-dimer, and not IL-6 or hs-CRP, is reduced over the
short term in those initiatingARV therapy.46 Additionally, the
reductions in LPS observed here are similar in magnitude to
those seen in a previous study47; the similar reductions in
the DRV/r and ATV/r arms suggest that these ARV agents
do not result in differential levels of LPS, a trigger of persis-
tent immune activation in ARV-treated individuals. In con-
trast, no decreases in hs-CRP were seen in either arm of this
study over 48weeks; this observation is in agreement with the
ACTG (AIDS Clinical Trials Group) A5095 study, which
demonstrated similar results in subjects receiving efavirenz-
based regimens over 96 weeks.48
During HIV infection, chronic viremia induces progressive
immune dysregulation characterized broadly by a decrease
in CD4+ cells and an increase in CD8+ cells and specifically
by elevated expression of CD38 and HLADR. This persis-
tent immune activation yields rapid and elevated lympho-
cyte turnover and a shift to an immunosenescent phenotype
(CD28-/CD57+ T cells).49,50 As expected, based on the results
of previous studies demonstrating the mitigating effect
of ARV therapy on these processes,51–53 the current study
found reductions in the proportion of activated T cells
(CD38-/HLADR+) in both the DRV/r and ATV/r arms.
Furthermore, the decline in the proportion of cells with
an immunosenescent phenotype (CD28-/CD57+) illustrates
the relationship between immune activation and im-
munosenescence and a critical immunologic benefit of ARV
therapy.
Individuals infected with HIV-1 have a higher risk of seri-
ous, non-AIDS conditions than do uninfected subjects.1 Given
that HIV infection is now considered a manageable chronic
disease, there is a growing level of attention focused on the
need for identification of metabolically favorable ARVs.
Atazanavir has generally been considered to have the most
favorable metabolic profile among PIs34 and was, therefore,
chosen as a comparator drug for this study. In the study
presented here, changes in metabolic parameters and bio-
markers from baseline with DRV/r were comparable to
changes observedwith ATV/r. These results are in agreement
with those seen in the TMC114-C159 trial, which investigated
metabolic changes in healthy subjects treated with DRV/r or
ATV/r over 28 days and observed similar mean changes in
lipid and glucose parameters between treatment groups.33
Table 5. Safety Parameters over 48 Weeks
DRV/r ATV/r
n = 34 n = 31
Adverse events, n (%)
Subjects with ‡ 1 AE 31 (91.2) 29 (93.5)
Subjects with ‡ 1 SAE 5 (14.7) 5 (16.1)
Subjects with ‡ 1 grade 3–4 AE 3 (8.8) 13 (41.9)
Subjects with ‡ 1 AE at least
possibly related to study drug
15 (44.1) 22 (71.0)
Grade 2–4 AEs at least possibly related to study drug,a
n (%)
Hyperbilirubinemia 0 3 (9.7)
Ocular icterus 0 2 (6.5)
Pollakiuria 0 2 (6.5)
Neutropenia 0 1 (3.2)
Diarrhea 1 (2.9) 0
Pancreatitis 1 (2.9) 0
Dehydration 1 (2.9) 0
Hypercholesterolemia 1 (2.9) 0
Joint swelling 0 1 (3.2)
Acute renal failure 1 (2.9) 0
Dermatitis 0 1 (3.2)
Leukocytoclastic vasculitis 0 1 (3.2)
Grade 2–4 laboratory abnormalities, n (%)
Glucose 4 (11.8) 3 (9.7)
Total cholesterol 3 (8.8) 1 (3.2)
Neutrophils 2 (5.9) 4 (12.9)
Low-density lipoprotein (direct) 2 (5.9) 3 (9.7)
Aspartate aminotransferase 2 (5.9) 0
Total bilirubin 1 (2.9) 27 (87.1)
Creatinine 1 (2.9) 1 (3.2)
Sodium 1 (2.9) 0
Triglycerides 0 1 (3.2)
aAdverse events reported as laboratory abnormalities are not
included.
DRV/r, darunavir/ritonavir; ATV/r, atazanavir/ritonavir; AE,
adverse event; SAE, serious adverse event.
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The TMC114-C159 trial did report significant differences in
the changes between treatment arms for insulin and the TC/
HDL ratio; these results, however, were not observed in
METABOLIK, which noted differences between arms only in
changes in TNF RII over 48 weeks.
The effect of some boosted PIs on insulin sensitivity re-
mains controversial. In contrast to some other PIs,8,10,11 no
clinically significant changes were seen in insulin sensitivity
in either the DRV/r or ATV/r arm of this study. Treatment
with indinavir and treatment with LPV/r have both been
associated with the development of insulin resistance in
healthy subjects9–11; however, other studies have demon-
strated that LPV/r does not affect insulin sensitivity in heal-
thy subjects.12,13 Atazanavir has generally had little effect on
insulin sensitivity in previous trials of HIV-negative sub-
jects,10,12 and switching from other PI-based therapies to
ATV/r has been shown to improve insulin sensitivity in HIV-
1-infected subjects.54 The results from this trial suggest that
DRV/r, likewise, has little impact on insulin sensitivity. It
should be noted that unlike the other studies cited here, which
used the euglycemic, hyperinsulinemic clamp technique, this
study used HOMA-IR as a measure of insulin resistance.
However, several studies have demonstrated that results
obtained usingHOMA-IR correlatewell with results using the
euglycemic, hyperinsulinemic clamp technique.36,55
Slight reductions in creatinine clearance were seen from
baseline to week 12 in both treatment arms of this study;
however, these reductions were no longer apparent after 48
weeks of treatment. A previous study suggested an associa-
tion between the use of ATV, TDF, or indinavir and creatinine
clearance, as indicated by a persistent reduction in glomerular
filtration rate over time.56 The biological explanations for
these findings are unclear, but may include glomerular dys-
function, high renal excretion rates, and/or crystalluria.56
Though the current study observed modest changes over 48
weeks, the ARTEMIS study did not show any changes in
creatinine clearance over 96 weeks,39 suggesting that long-
term use of DRV/r has little effect on creatinine clearance.
The small increases in TAT and SAT seen in this study are
similar to those seen in previous trials of boosted PIs and
nucleoside reverse transcriptase inhibitors (NRTIs) in treat-
ment-naive subjects.19–22,24 Increases in abdominal fat and
waist size have been associated with increased cardiovascular
risk factors in HIV-1-infected subjects, suggesting a need to
monitor even small changes in fat distribution in this popu-
lation. The increase in PAT seen with DRV/r treatment in this
study was in contrast to data from other studies, which have
reported decreases in PAT in HIV-1-infected individuals re-
ceiving other ARVs.19,20,22 Although some studies have
demonstrated an association between lipoatrophy and use of
specific PIs or NRTIs,19,22 others have shown no ARV-specific
effects,20 and it has been observed that HIV-1-infected sub-
jects, in general, have lower levels of PAT compared with
uninfected control subjects.57 The increase in PAT in the
DRV/r arm of this study, which had more advanced disease
at baseline compared with the ATV/r arm, can be considered
as potentially favorable; however, the small sample size
and short duration of this trial limit clinical interpretation of
these data.
In this study, despite slight increases in VAT and SAT,
subjects’ perceptions of their body changes generally im-
proved or remained constant over time. The results from the
ABCD questionnaire are in line with those from a previous
study, which demonstrated improvements in ABCD scores
over 48 weeks of DRV/r-based therapy.30 In both treatment
arms, the question ‘‘In the past 4 weeks has your belt or waist
size increased?’’ had the greatest increase in subjects an-
swering ‘‘yes’’ at 48 weeks compared with baseline; this result
is consistent with the increases in VAT and SAT seen during
the trial. Although changes in adipose tissue distribution over
the study period were similar between arms, more DRV/r
subjects reported increases in waist and chest size compared
with ATV/r subjects. This discrepancy may indicate subtle
differences in lipodystrophy and lipoatrophy between the
two treatment regimens, ormay have been partially due to the
differences in racial distribution between the two study arms.
Both regimens had favorable safety profiles, with low in-
cidences of AEs and laboratory abnormalities; the increased
incidence of grade 2–4 hyperbilirubinemia or grade 2–4 in-
creased total bilirubin in the ATV/r armwas expected, as they
are known side effects of ATV/r-based therapy.34,58 Similar to
the results obtained here, safety results from ARTEMIS sug-
gested low rates of grade 2–4 AEs, including gastrointestinal
and renal AEs, in subjects receiving DRV/r over 96 weeks.39
Subjects receiving DRV/r in ARTEMIS had a significantly
lower rate of diarrhea compared with LPV/r subjects (4% vs.
11%, respectively) and, in line with results from this trial, no
clinically relevant changes were seen in creatinine clearance in
either treatment arm.
Interpretation of the data reported in this pilot study may
be limited by the small sample size, as well as the fact that the
trial was not powered to test for statistical significance, but
was rather intended to be an exploratory analysis. The var-
iation seen between arms in certain baseline characteristics,
despite the randomized study design, is likely related to the
small sample size. Somewhat larger changes in TC and
apoA1 with DRV/r versus ATV/r, particularly at week 12,
are likely due to lower baseline values of these parameters in
the DRV/r arm. Likewise, the larger reduction in TNF RII is
likely due to the higher baseline value in the DRV/r arm.
Additionally, it should be noted that subjects with abnormal
lipid or glucose levels were excluded from the trial and may
not, therefore, be reflective of the overall HIV-1-infected
population. Despite these limitations, the equally favorable
metabolic profile observed with DRV/r-based therapy when
compared with ATV/r-based therapy warrants further in-
vestigation. It is noteworthy that the ACTG is conducting a
large study of approximately 1800 treatment-naive, HIV-1-
infected subjects receiving DRV/r, ATV/r, or raltegravir (all
receiving fixed-dose FTC/TDF in the background regimen);
end points from this study include changes in metabolic
parameters over 144 weeks (clinicaltrials.gov identifier:
NCT00811954). This study is statistically powered to defin-
itively evaluate whether DRV/r-based therapy and ATV/r-
based therapy are characterized by similarly favorable
metabolic profiles.
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